CLOs on the Move

Amicus Therapeutics

www.amicusrx.com

 
Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. With one rare disease medicine globally commercialized for Fabry disease, an investigational enzyme replacement therapy (AT-GAA) in late stage development for the treatment of Pompe disease, and a robust gene therapy pipeline and growth platform for lysosomal storage disorders, we are committed to changing the lives of people with these life-threatening conditions. Across the organization, our team is united by our passion for making a difference, and committed to pushing ideas as far and as fast ...
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.amicusrx.com
  • 1 Cedar Brook Drive
    Cranbury, NJ USA 08512
  • Phone: 609.662.2000

Executives

Name Title Contact Details
Sergey Tesler
Executive Director, Global Regulatory Strategy, CMC Profile
Patrik Florencio
SVP, Global Chief Compliance and Risk Officer Profile
Ellen Rosenberg
Chief Legal Officer Profile
Heather Ramirez
Executive Director - Lead Counsel US Profile

Similar Companies

U.S. Dermatology Partners

We combine the personal care found in private dermatology practices with the benefits of a network of physicians working together.

Tavotek Biotherapeutics

Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.

Avadim Health

Avadim Health is a life sciences company that offers advanced, safe solutions in everything from immune health to neuromuscular care. They are committed to helping those in need benefit from their products and have a strong pipeline across a broad rang...

The Harvard Drug Group

The Harvard Drug Group is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Jaguar Animal Health

Jaguar Animal Health is a company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals. Our products are designed with a thorough understanding of not only species-specific health issues, but also market practices, the economics of current treatment strategies, competitive dynamics, government initiatives, such as concern for extensive antibiotic usage, and effective channels for new product introductions. In addition to Canalevia™ for dogs and Neonorm™ for preweaned dairy calves, we are developing formulations of these products across multiple animal species and market channels. Our management team has significant experience in gastrointestinal and animal health product development. This experience includes the development of crofelemer for human use, from discovery and preclinical and clinical toxicity studies, including the existing animal studies to be used for Canalevia™ regulatory approvals, through human clinical development. Our team also includes individuals who have prior animal health experience at major pharmaceutical companies, including Ciba-Geigy Corp., now Novartis International AG, SmithKline Beecham Corporation, now GlaxoSmithKline LLC, and the animal health group of Pfizer Inc., now Zoetis Inc.